STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

Dexcom (DXCM) director shifts 11,462 shares via bona fide gift transfers

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dexcom Inc. director Mark G. Foletta reported non-market transfers of Dexcom common stock classified as bona fide gifts. On 2026-05-08, he disposed of a total of 11,462 shares at a stated price of $0.00 per share, reflecting that no cash was received.

One transaction moved 5,731 directly held shares to the Mark G. and Mary E. Foletta Family Trust, and a second transaction reduced his remaining directly held shares by another 5,731. After these transfers, 56,852 shares are held indirectly through the family trust, while his direct holdings are reported as zero.

Positive

  • None.

Negative

  • None.
Insider FOLETTA MARK G
Role null
Type Security Shares Price Value
Gift Common Stock 5,731 $0.00 --
Gift Common Stock 5,731 $0.00 --
Holdings After Transaction: Common Stock — 0 shares (Direct, null); Common Stock — 56,852 shares (Indirect, by Trust)
Footnotes (1)
  1. Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.
Gifted shares total 11,462 shares Bona fide gifts of common stock on May 8, 2026
Gift transaction size 5,731 shares Each of two separate gift transactions
Price per share $0.00 per share Reported for both bona fide gift transactions
Indirect holdings after 56,852 shares Shares held by the Mark G. and Mary E. Foletta Family Trust after gifts
Direct holdings after 0 shares Directly held Dexcom common stock following the transactions
Gift transactions count 2 transactions Both coded as G for bona fide gift
bona fide gift financial
"transaction_code_description: Bona fide gift"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
restricted stock units financial
"upon vesting of previously awarded restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
indirect ownership financial
"ownership_type: indirect and nature_of_ownership: by Trust"
trustee financial
"with respect to which the reporting person is a trustee"
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FOLETTA MARK G
(Last)(First)(Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026G5,731(1)D$00D
Common Stock05/08/2026G5,731(1)A$056,852Iby Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units.
2. Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.
Remarks:
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Mark G. Foletta05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Dexcom (DXCM) director Mark G. Foletta report?

Mark G. Foletta reported two bona fide gift transactions involving Dexcom common stock. He disposed of 11,462 shares in total on May 8, 2026, with no cash received, reflecting non-market transfers rather than open-market sales.

How many Dexcom (DXCM) shares did Mark G. Foletta transfer and at what price?

Foletta transferred 11,462 Dexcom common shares in total, split into two 5,731-share transactions. The reported price per share was $0.00, indicating these were bona fide gifts and not sales for cash in the open market.

How many Dexcom (DXCM) shares does Mark G. Foletta report owning after the gifts?

After the reported gifts, Foletta’s direct Dexcom holdings are shown as zero shares. He reports indirect ownership of 56,852 shares held by the Mark G. and Mary E. Foletta Family Trust, where he serves as a trustee.

Were the Dexcom (DXCM) insider transactions open-market buys or sells?

The transactions were not open-market buys or sells. They are coded as “G” for bona fide gifts, with a transaction price of $0.00 per share, indicating transfers of shares without cash proceeds changing hands.

What role does the family trust play in Mark G. Foletta’s Dexcom (DXCM) holdings?

Shares are held by the Mark G. and Mary E. Foletta Family Trust, with Foletta as a trustee. The Form 4 shows 56,852 Dexcom shares held indirectly through this trust following the May 8, 2026 gift transactions.

Do the Dexcom (DXCM) Form 4 gifts involve restricted stock units (RSUs)?

A footnote explains that shares were transferred to the family trust upon vesting of previously awarded restricted stock units. This links the indirect holdings to earlier equity compensation that vested and was subsequently moved into the trust.